GlaxoSmithKline (Belgium)

Recent papers from GlaxoSmithKline (Belgium)

1. Respiratory syncytial virus in adults aged ≥ 50 years in the Netherlands: a database and time-series modelling analysis (2013–2020)Infection · 2026
2. Risk of herpes zoster in patients with cardiovascular diseases: a systematic literature review and meta-analysisEuropean Heart Journal · 2026
3. Herpes zoster impacts the time to first change in diuretic treatment and healthcare resource utilisation in patients with heart failureEuropean Heart Journal · 2026
4. Public Health Impact of Adjuvanted RSVPreF3 Vaccination Among US Adults Aged ≥60 Years Residing in Long-Term Care SettingsJournal of the American Medical Directors Association · 2026
5. A Phase 2 Trial Evaluating the Immunogenicity and Safety of an mRNA-Based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and NeuraminidaseInfectious Diseases and Therapy · 2026
6. A Phase 1/2 Trial Evaluating the Safety and Immunogenicity of an mRNA-based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and NeuraminidaseInfectious Diseases and Therapy · 2026
7. Innovative roadmaps for sustainable antimicrobial resistance interventionsScience Translational Medicine · 2026
8. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control studyThe Lancet · 2013
9. Uncovering lung virome signatures of COPD severity and acute exacerbations in longitudinally sampled AERIS cohortnpj Biofilms and Microbiomes · 2026
10. Summary of 2025 Society of Toxicology Workshop “Vaccine Toxicology in the Post-COVID Era”Vaccine · 2026
11. Health Outcomes, Healthcare Resource Use, and Economic Burden of Invasive Meningococcal Disease in the United States Among Children Aged <11 YearsPharmacoEconomics - Open · 2026
12. Challenges and Burdens in Refractory Chronic Cough: Patients’ and Physicians’ PerspectivesPulmonary Therapy · 2026
13. United States healthcare providers’ views on pediatric meningococcal disease and vaccinationExpert Review of Vaccines · 2026
14. Herpes zoster incidence rates in adults aged 18 years or older with immunocompromising or chronic conditions in England: a large retrospective cohort study (Clinical Practice Research Datalink, 2012–2019)BMJ Open · 2026
15. Both ageing and frailty status impact vaccine-induced transcriptomic profiles and subsequent humoral immunity: results from the VITAL cohort2026
16. Genetic characterization of M. tuberculosis isolates from participants in a Phase 2b randomized trial evaluating the M72/AS01E tuberculosis candidate vaccineThe Journal of Infectious Diseases · 2026
17. A randomized trial of viral vector and adjuvanted protein HBV therapeutic vaccine in people with chronic hepatitis B on nucleos(t)ide analogsHepatology Communications · 2026
18. Optimising Pharmacovigilance Efficiency with MLIT (Machine Learning for Intelligent Triage): A Tool for Statistical Safety AlertsDrug Safety · 2026
19. Cost-effectiveness of a single dose of the adjuvanted respiratory syncytial virus preFusion protein 3 vaccine over 5 years and its potential public health impact among older adults in ItalyThe European Journal of Health Economics · 2026
20. AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety SurveillanceDrug Safety · 2026